Skip to main content
. 2021 Sep 9;24(5):417–427. doi: 10.4048/jbc.2021.24.e41

Figure 2. DFS and OS according to the development of NAFLD during treatment.

Figure 2

(A) The median DFS was 59.3 months (95% CI, 45.5–73.0) in the non NAFLD group; whereas in the NAFLD group the median DFS was not reached (HR, 0.386; 95% CI, 0.19–0.77; p = 0.007). (B) The survival estimation of breast cancer patients who developed NAFLD was not different from that of non-NAFLD patients: mean survival was 108.23 ± 3.525 months vs. 87.79 ± 1.283 months. The median survival estimation of both groups was not reached (HR for OS, 0.294; 95% CI, 0.035–2.446; p = 0.257).

DFS = disease-free survival; OS = overall survival; NAFLD = non-alcoholic fatty liver disease; CI = confidence interval; HR = hazard ratio.